Michael Oluwatosin Gabriel

Michael Oluwatosin Gabriel

Auto-generated profile, based on publicly available information

Michael Oluwatosin Gabriel

Centre of New Technologies, University of Warsaw, Poland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2024
Verified
Book Chapter
Closed access
PDF file
Adejoke MemuduAdejoke Memudu
Adejoke Memudu
MGMichael Oluwatosin Gabriel
Michael Oluwatosin Gabriel
VAVictor Ebube Anadu
Victor Ebube Anadu
OIOlayemi Kafilat Ijomone
Olayemi Kafilat Ijomone
OIOmamuyovwi Ijomone
Omamuyovwi Ijomone
Neurodegenerative diseases (NDs) including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amongst others, pose significant challenges in terms of brain targeted drug delivery. The blood-brain barrier (BBB) limits the passage of substance into the brain including potential therapeutics, hence hindering their efficacy in treating NDs. Nanoparticles are promising carriers for brain targeted drug delivery as result of their design with potential to bypass the BBB. These nanoparticles are made from natural (organic) and artificial (inorganic) manipulations of substances such as metal, carbon-based materials, liposomal, polymeric, proteins, polysaccharides fullerenes, nanoemulsions, coffee, chitosan etc. Nanoparticles are engineered to encapsulate drugs thereby protecting, controlled release, and enhanced drug stability in addition to its surface modifications with ligands that facilitate receptor- driven transport across the BBB, promoting targeted drug passage to specific regions of the brain by neurodegenerative disorders. Furthermore, nanoparticles even though are small sized, they have versatile therapeutics, that enables the delivery of different types of drugs with potential neuroprotective, anti-inflammatory, or neurodegenerative properties, addressing the multifactorial nature of neurodegenerative disorders. In this chapter, we discuss nanoparticles therapeutics in NDs, their characteristics, mechanisms through which they can be used to target brain regions as well as reported therapeutics applications to specific NDs including AD, PD, HD, Prion disease, Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis. <!----> <!----> <!----> <!---->

13 August 2024
Verified
Book Chapter
Closed access
PDF file
Adejoke MemuduAdejoke Memudu
Adejoke Memudu
MGMichael Oluwatosin Gabriel
Michael Oluwatosin Gabriel
GAGrace Temitope Akingbade
Grace Temitope Akingbade
HIHappiness Ochi Inyang
Happiness Ochi Inyang
OIOmamuyovwi Ijomone
Omamuyovwi Ijomone
The blood circulation in the nervous system is separated from the brain through an important and highly specialized physiological barrier known as the blood–brain barrier (BBB), which plays a critical function in the maintenance of brain homeostasis through the regulation of passage of substances into and out of the brain. In neurodegenerative conditions characterized by neuroinflammation or brain injury, the normal integrity of the BBB becomes disrupted, leading to aberration in the BBB membrane integrity, resulting in an increased permeability and abnormal barrier function. The distortion of the structural arrangement of the BBB renders it permeable to immune cells, toxins, pathogens, and pro-inflammatory mediators gaining access into the brain, which triggers a cascade of biological activities, such as increased neuroinflammation, oxidative stress, and neuronal damage; this influences the progression of neurodegenerative conditions. Understanding the processes underlying BBB disruption is critical for developing therapeutic strategies to restore BBB integrity and prevent the detrimental consequences of barrier dysfunction in NDs. Some of the processes of BBB distortion include changes in the tight junction proteins, inflammatory mediators, matrix metalloproteinases, and oxidative stress. Elucidating these mechanisms can aid in the spotting of likely therapeutic target site and the invention of interventions to prevent or minimize BBB dysfunction NDs via nanomedicine-based drug docking systems to improve drug transport through the BBB. In summary, disruption of the blood–brain barrier is significant in the pathogenesis of various brain disorders. The knowledge of the underlying mechanisms and developing targeted interventions to restore BBB integrity are essential for improving disease outcomes and facilitating the advancement of effective remedies for brain diseases, resulting in improved treatment outcomes of various neurological conditions. <!----> <!----> <!----> <!---->

5 November 2023 in IBRO Neuroscience Reports
Verified
Journal Article
Open access
MGMichael Gabriel
Michael Gabriel
MLMarcin Lipiec
Marcin Lipiec
JBJoanna Bem
Joanna Bem
MWMarta Wiśniewska
Marta Wiśniewska

13 August 2024
Verified
Book Chapter
Closed access
PDF file
Adejoke MemuduAdejoke Memudu
Adejoke Memudu
MGMichael Oluwatosin Gabriel
Michael Oluwatosin Gabriel
The blood–brain barrier (BBB) is a highly selective and dynamic semi-permeable membrane formed by tight junctions between the endothelial cells that line the capillaries of the brain, which restrict the passage of certain molecules, ions, and cells from the blood into the brain, while maintaining the brain’s homeostasis and preventing the entry of harmful substances into the brain. In neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, characterized by the progressive loss of neurons and cognitive impairment, the BBB becomes compromised, leading to the infiltration of toxic substances and immune cells into the brain, resulting in a compromised neuronal function, leading to neurodegeneration. Several reports have shown that BBB dysfunction is a hallmark of neurodegenerative disorders, and disruption of the BBB is associated with the accumulation of toxic proteins, oxidative stress, neuroinflammation, and neuronal damage. The underlying mechanisms of BBB dysfunction in neurodegenerative disorders are complex and multifactorial, involving alterations in the expression and function of tight junction proteins, transporters, and enzymes. Understanding the role of the BBB in neurodegenerative disorders is crucial to the development of effective therapies for these devastating diseases. Novel drug delivery systems or therapeutic strategies targeting the BBB could be a promising approach to treating these disorders. These strategies include the use of drugs that enhance BBB integrity, the development of targeted drug delivery systems that can cross the BBB, and the modulation of BBB transporters to enhance the clearance of toxic proteins. In summary, the BBB plays a crucial role in the pathogenesis and progression of neurodegenerative disorders, and targeting the BBB represents a promising avenue for the development of novel therapies for these devastating diseases. <!----> <!----> <!----> <!---->

14 November 2025 in bioRxiv
Verified
Preprint
Open access
ANAndrzej Nagalski
Andrzej Nagalski
KKKamil Koziński
Kamil Koziński
SBSuelen Baggio
Suelen Baggio
ŁSŁukasz M. Szewczyk
Łukasz M. Szewczyk
MLMarcin A. Lipiec
Marcin A. Lipiec
MWMarta B. Wiśniewska
Marta B. Wiśniewska
Psychiatric and metabolic disorders often co-occur. While shared genetic factors and cellular dysfunctions are implicated, the underlying molecular mechanisms remain poorly understood. TCF7L2, a risk gene for type 2 diabetes and autism spectrum disorder, is highly expressed in the thalamus—a brain region extensively interconnected with the cortex, playing a key role in sensory processing, motor control, and behavioral regulation. Given its known role as a transcription factor regulating systemic energy metabolism, we explored its potential contribution to brain metabolism and behavior. To this end, we used a conditional knockout model with postnatal TCF7L2 loss in the thalamus and partial deficiency in the pancreas. Tcf7l2 knockout mice exhibited social deficits and reduced motor habituation. In parallel, they also developed systemic glucose intolerance, modelling the psychiatric-metabolic comorbidity. Thalamic depletion of TCF7L2 resulted in elevated inhibitory phosphorylation of the pyruvate dehydrogenase —an enzymatic gatekeeper for pyruvate utilization in energy production—in the thalamus and cortex. This was accompanied by altered thalamic and cortical metabolism, characterized by reduced efficiency of pyruvate oxidation alongside enhanced oxidation of fatty acids and ketone bodies. Notably, a ketogenic diet alleviated metabolic dysregulation in the brain and normalized some social behaviors in knockout mice. These findings suggest that impaired energy metabolism in the thalamocortical circuitry may represent one of the pathogenic mechanisms underlying neuropsychiatric symptoms.

29 December 2025 in bioRxiv
Verified
Preprint
Open access
MGMichael O Gabriel
Michael O Gabriel
JBJoanna Bem
Joanna Bem
MLMarcin A Lipiec
Marcin A Lipiec
AAAbhishek Agarwal
Abhishek Agarwal
ELEwa Liszewska
Ewa Liszewska
MWMarta B Wisniewska
Marta B Wisniewska
Alternative isoforms of transcription factors are common during brain development, but their functional significance remains poorly defined. One example is TCF7L2, a transcription factor critical for developing the thalamus and autism spectrum-associated gene. It exists in two isoforms from different promoters: the long isoform (L-TCF7L2) with the β-catenin-binding domain, and the shorter isoform (S-TCF7L2), lacking this domain and classically considered a dominant-negative regulator of the L isoform. Here, we investigated the role of TCF7L2 isoforms in thalamic development using total and isoform-specific knockout strategies. Analysis of axonal phenotypes, regional markers, and RNA-seq uncovered that the isoforms are functionally redundant during development. Immunohistochemistry and ChIP-seq showed that in the embryonic thalamus — unlike in the postnatal thalamus — TCF7L2 regulates gene expression independently of β-catenin. These findings reveal a switch from β-catenin–independent and isoform-redundant to classical β-catenin–dependent TCF7L2 activity, occurring between the embryonic and postnatal stages. This suggests that alternative promoter usage may, in some contexts, ensure robust availability of the regulatory protein during brain development.